MDB Capital Holdings, LLC Class A common Q4 FY2025 earnings call

Chris Marlett discussed the company's journey, starting with launching companies every 18 months and going public to scale to 3 - 5 launches a year. AI is a game - changer for the business, compressing time for deep diligence. MDB Direct's clearing operation is a valuable asset with potential for strategic partnerships. PatVest has become a law firm with core operations of a law firm. Portfolio assets like Exozymes and Pollux have billion - dollar potential. The company has about $10 million in fixed operating expenses and burned about $5.7 million in cash flow for the year.

The company is positioned to launch 3 - 5 high - quality companies a year, depending on solving distribution issues. They aim to spin out clearing platform and PatVest, and improve cost scale efficiency.

Macro and global risk, microcap market conditions risk, execution risk (including portfolio companies' execution), distribution gap risk, clinical and regulatory risk.

Q: Can you talk about ClearSign, HeartBeam, Buddha, QBIO?

A: ClearSign's burner technology is relevant, HeartBeam has a game - changing ECG, Buddha is in a big market opportunity, QBIO has challenges but valuable technology.

Q: What about Exozyme's dilution?

A: Exozymes has $10 million in OpEx to create big opportunities, dilution is relatively minimal as opportunities are near commercialization.

Q: Consider SAS model for Pat Invest?

A: SaaS will be crushed by AI, as AI can do patentability analysis much faster and better with expert analysts and AI.

Q: Deal pipeline?

A: Deal pipeline is good but distribution is the constraint, community is small and trying to broaden distribution.